MicroRNA-141 is a tumor regulator and prognostic biomarker in human glioblastoma

Xiong,Xuehua; Deng,Jianping; Zeng,Chun; Jiang,Yongming; Tang,Shuang; Sun,Xiaochuan

doi:10.3892/ol.2017.6735

MicroRNA-141 is a tumor regulator and prognostic biomarker in human glioblastoma

Authors:
- Xuehua Xiong
- Jianping Deng
- Chun Zeng
- Yongming Jiang
- Shuang Tang
- Xiaochuan Sun
View Affiliations

Affiliations: Department of Neurosurgery, Suining Central Hospital, Suining, Sichuan 629000, P.R. China, Department of Neurosurgery, Chongqing Fourth People's Hospital, Chongqing 400014, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: August 9, 2017 https://doi.org/10.3892/ol.2017.6735
Pages: 4455-4460
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human glioblastoma is one of the most malignant types of brain tumor in the world. In the present study, the functional mechanisms of microRNA‑141 (miR‑141) were assessed, and the potential role of miR‑141 as a prognostic biomarker in glioblastoma was examined. The gene expression of miR‑141 in glioblastoma cell lines and glioblastoma tumors was assessed by reverse transcription‑quantitative polymerase chain reaction. Glioblastoma LN229 and U89 cell lines were transfected with synthetic miR‑141 mimics to upregulate endogenous miR‑141. The subsequent effect on glioblastoma proliferation was assessed by MTT assay. In human glioblastoma, miR‑141 expression was compared between patients with tumors of different pathological grades. Statistical analyses were performed to assess the correlation between miR‑141 and the clinicopathological properties and overall survival rates (OS) of the patients. In addition, a Cox regression model was used to examine whether miR‑141 was a potential biomarker of glioblastoma. miR‑141 was aberrantly downregulated in glioblastoma cell lines and human glioblastoma tumors. Forced miR‑141 upregulation in glioblastoma LN229 and U89 cell lines suppressed cancer proliferation. In patients with glioblastoma, miR‑141 downregulation was closely associated with an advanced disease stage, poor clinicopathological properties and a shorter OS time. The multivariate Cox regression model demonstrated that low miR‑141 expression was an effective prognostic biomarker for patients with glioblastoma. Overall, the present study showed that miR‑141 may be a functional cancer regulator and a prognostic biomarker for glioblastoma.

View Figures

View References

1	Alifieris C and Trafalis DT: Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ellis HP, Greenslade M, Powell B, Spiteri I, Sottoriva A and Kurian KM: Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol. 5:2512015. View Article : Google Scholar : PubMed/NCBI
3	Jovčevska I, Kočevar N and Komel R: Glioma and glioblastoma - how much do we (not) know? Mol Clin Oncol. 1:935–941. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kapoor A, Mohindra S, Singla N, Sodhi HB, Chatterjee D and Gupta SK: Multiple glioblastoma: A diagnostic challenge and controversies in management. Neurol India. 63:449–452. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhang M, Ye G, Li J and Wang Y: Recent advance in molecular angiogenesis in glioblastoma: The challenge and hope for anti-angiogenic therapy. Brain Tumor Pathol. 32:229–236. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cloughesy TF, Cavenee WK and Mischel PS: Glioblastoma: From molecular pathology to targeted treatment. Annu Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
7	Guarnieri DJ and DiLeone RJ: MicroRNAs: A new class of gene regulators. Ann Med. 40:197–208. 2008. View Article : Google Scholar : PubMed/NCBI
8	Erson AE and Petty EM: MicroRNAs in development and disease. Clin Genet. 74:296–306. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhao S and Liu MF: Mechanisms of microRNA-mediated gene regulation. Sci China C Life Sci. 52:1111–1116. 2009. View Article : Google Scholar : PubMed/NCBI
10	Nelson KM and Weiss GJ: MicroRNAs and cancer: Past, present, and potential future. Mol Cancer Ther. 7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kohlhapp FJ, Mitra AK, Lengyel E and Peter ME: MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 34:5857–5868. 2015. View Article : Google Scholar : PubMed/NCBI
12	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Chen J and Sen S: MicroRNA as biomarkers and diagnostics. J Cell Physiol. 231:25–30. 2016. View Article : Google Scholar : PubMed/NCBI
15	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
16	Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M and Duroux M: A systematic review of microRNA in glioblastoma multiforme: Micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol. 47:131–144. 2013. View Article : Google Scholar : PubMed/NCBI
17	Xue J, Niu YF, Huang J, Peng G, Wang LX, Yang YH and Li YQ: miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014. View Article : Google Scholar : PubMed/NCBI
18	van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, et al: miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 32:4284–4293. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tejero R, Navarro A, Campayo M, Vinolas N, Marrades RM, Cordeiro A, Ruiz-Martinez M, Santasusagna S, Molins L, Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
20	Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, et al: miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
21	Feiden S and Feiden W: WHO classification of tumours of the CNS: Revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas. Pathologe. 29:411–421. 2008.(In German). View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T and Si J: Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol. 44:556–561. 2009. View Article : Google Scholar : PubMed/NCBI
24	Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR and Futscher BW: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
25	Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 6:e177452011. View Article : Google Scholar : PubMed/NCBI
26	Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI